Diabetic Ulcers
12
3
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
MicroMatrix® Flex in Tunneling Wounds
Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds
PMCF Study of Debridement Pad
Retrospective, Multi-center Real-world Study of StimLabs Human Placental Membrane Tissue to Treat Hard-to-Heal Wounds
Comparison of Platelet-Rich Plasma Dressing and Normal Saline Dressing for Wound Healing in Patients With Chronic Diabetic Wounds
Genetic Markers of Diabetic Ulcers and Personalized Treatment Targets Research
Sterile Wound Care Liquid Dressing in Treatment of Diabetic Ulcer in Necrosis Stable Stage: a Randomized Control Trial
Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers
Prospective PuraPly™ AM Case Series Study
Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing